Karyopharm Therapeutics | KPTI - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.58B 316M 2026-03
Abbott USD 3.27B 138M 2026-03
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Incyte USD 328.1M 62.31M 2026-03
J&J USD 6.03B 719M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.67B 180M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.14B 296M 2026-03
Novartis USD 3.44B 132M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Takeda JPY 292B 9.21B 2026-03
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
TG Therapeutics USD 73.14M 22.42M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Xencor USD 82.12M 65.08M 2026-03